Who are Placebo capsules, Letrozole, Anastrozole, Tamoxifen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-capsules-letrozole-anastrozole-tamoxifen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Placebo capsules, Letrozole, Anastrozole, Tamoxifen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo capsules, Letrozole, Anastrozole, Tamoxifen (Placebo capsules, Letrozole, Anastrozole, Tamoxifen) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatase inhibitor, SERM. Area: Oncology.

phase 3 Aromatase inhibitor, SERM Aromatase, Estrogen receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo capsules, Letrozole, Anastrozole, Tamoxifen (Placebo capsules, Letrozole, Anastrozole, Tamoxifen) — Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Letrozole and Anastrozole are aromatase inhibitors, which block the production of estrogen in the body. Tamoxifen is a selective estrogen receptor modulator (SERM), which blocks estrogen receptors in breast tissue.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo capsules, Letrozole, Anastrozole, Tamoxifen TARGET	Placebo capsules, Letrozole, Anastrozole, Tamoxifen	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Aromatase inhibitor, SERM	Aromatase, Estrogen receptor
TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen	TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	phase 3	Aromatase inhibitor, Selective estrogen receptor modulator	Aromatase, Estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aromatase inhibitor, SERM class)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo capsules, Letrozole, Anastrozole, Tamoxifen — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-capsules-letrozole-anastrozole-tamoxifen. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab